Total debt is minimal at about $1.2M and the D/E ratio is near zero, but cash of $55.7M against quarterly operating outflows near $50M suggests liquidity may be thin despite a current ratio of 30.02.
Dianthus Therapeutics, Inc. (DNTH) balance sheet — 10-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Total Current Assets | 856.04M | 409.44M | 280.9M | 177.45M | 82.03M | 180.69M | 151.53M | 149.84M | 145.32M | 52.5M | 10.83M |
| Cash & Short-Term Investments | 837.78M | 404.3M | 275.24M | 173.72M | 75.49M | 176.93M | 148.84M | 145.73M | 142.57M | 51.57M | 4.54M |
| Cash Only | 55.69M | 51.09M | 22.79M | 132.32M | 15.37M | 131.65M | 58.15M | 65.07M | 58.34M | 51.57M | 4.54M |
| Short-Term Investments | 782.1M | 353.21M | 252.45M | 41.39M | 60.13M | 45.28M | 90.68M | 80.66M | 84.22M | 0 | 0 |
| Accounts Receivable | 582K | 102K | 807K | 478K | 5.64M | 0 | 0 | 0 | 0 | 0 | 6.25M |
| Days Sales Outstanding | 67.82 | 18.29 | 47.24 | 61.74 | 320.69 | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 169K | 5.04M | 355K | 504K | 53K | 3.77M | 2.69M | 4.11M | 2.75M | 936K | 41K |
| Total Non-Current Assets | 420.21M | 121.48M | 93.1M | 1.95M | 1.08M | 9.24M | 10.09M | 11.67M | 11.99M | 1.96M | 508K |
| Property, Plant & Equipment | 1.9M | 1.63M | 1.75M | 800K | 956K | 7.46M | 8.31M | 9.89M | 3.07M | 1.74M | 508K |
| Fixed Asset Turnover | 1.61x | 1.25x | 3.57x | 3.53x | 6.71x | 0.20x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 933.68M | 110.14M | 81.73M | 0 | 0 | 1.78M | 1.78M | 1.78M | 8.92M | 218K | 0 |
| Other Non-Current Assets | 12.27M | 9.72M | 9.63M | 1.15M | 121K | 0 | 0 | 0 | 0 | 4K | 0 |
| Total Assets | 1.28B | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M | 161.62M | 161.51M | 157.31M | 54.46M | 11.34M |
| Asset Turnover | 0.00x | 0.00x | 0.02x | 0.02x | 0.08x | 0.01x | - | - | - | - | - |
| Asset Growth % | 692.76% | 41.95% | 108.47% | 115.86% | -56.24% | 17.52% | 0.07% | 2.67% | 188.84% | 380.19% | - |
| Total Current Liabilities | 28.52M | 30.73M | 18.45M | 9.63M | 8.22M | 10.86M | 11.43M | 14.12M | 10.42M | 4.14M | 2.3M |
| Accounts Payable | 5.5M | 9.72M | 4.58M | 2.61M | 1.17M | 3.04M | 3.76M | 2.81M | 3.49M | 167K | 1.67M |
| Days Payables Outstanding | 32.28K | - | - | - | - | - | 693.83 | 556.91 | 1.46K | 162.11 | 101.41K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 5.79M | 1.19M | 479K | 100K | 100K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 9.52M | 5.15M | 5.36M | 2.08M | 4.48M | 4.56M | 8.06M | 4.4M | 2.65M | 127K |
| Current Ratio | 30.02x | 13.32x | 15.22x | 18.42x | 9.97x | 16.63x | 13.26x | 10.62x | 13.95x | 12.68x | 4.71x |
| Quick Ratio | 30.02x | 13.32x | 15.22x | 18.42x | 9.97x | 16.63x | 13.26x | 10.62x | 13.95x | 12.68x | 4.71x |
| Cash Conversion Cycle | -32.21K | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.31M | 6.79M | 3.08M | 904K | 1.23M | 6.4M | 6.28M | 6.21M | 1.25M | 0 | 0 |
| Long-Term Debt | 0 | 1.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 1.77M | 0 | 1.17M | 168K | 438K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 6.4M | 6.28M | 6.21M | 1.25M | 0 | 0 |
| Total Liabilities | 34.82M | 37.52M | 21.53M | 10.54M | 9.45M | 17.26M | 17.71M | 20.32M | 11.66M | 4.14M | 2.3M |
| Total Debt | 1.21M | 1.39M | 1.49M | 585K | 788K | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -54.48M | -49.7M | -21.3M | -131.74M | -14.58M | -131.65M | -58.15M | -65.07M | -58.34M | -51.57M | -4.54M |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | - | - | - | - | - | - |
| Debt / EBITDA | -0.01x | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.23x | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | -19.90x | - | - | - | -56.86x |
| Total Equity | 1.24B | 493.4M | 352.48M | 168.87M | 73.66M | 172.67M | 143.91M | 141.19M | 145.65M | 50.32M | 9.04M |
| Equity Growth % | 719.44% | 39.98% | 108.73% | 129.27% | -57.34% | 19.99% | 1.92% | -3.06% | 189.44% | 456.53% | - |
| Book Value per Share | 21.65 | 13.05 | 10.58 | 32.77 | 19.66 | 50.28 | 52.42 | 61.03 | 69.95 | 22.76 | 4.09 |
| Total Shareholders' Equity | 1.24B | 493.4M | 352.48M | 168.87M | 73.66M | 172.67M | 143.91M | 141.19M | 145.65M | 50.32M | 9.04M |
| Common Stock | 56K | 43K | 31K | 15K | 0 | 59K | 49K | 39K | 33K | 6K | 3K |
| Retained Earnings | -474.42M | -336.73M | -174.39M | -89.42M | -45.87M | -325.57M | -254.43M | -179.5M | -102.73M | -45.21M | -9.72M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -6.28M | 489K | 106K | 47K | -161K | -30K | -23K | 8K | -8K | -382K | -6K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying DNTH stock.
As of 2025, Dianthus Therapeutics, Inc. (DNTH) had total assets of $530.9M including $409.4M in current assets.
Dianthus Therapeutics, Inc. (DNTH) carries total debt of $1.4M, offset by $404.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Dianthus Therapeutics, Inc. (DNTH) has total shareholders' equity (book value) of $493.4M ($13.05 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Dianthus Therapeutics, Inc. (DNTH) reported a current ratio of 13.32x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Cash runway shortfall and dilution
Metrics are mathematically derived from official filings.
Equity Base Expanding Through Financing Events
Based on reported figures, DNTH's total assets rose from $354.2M in 2024Q3 to $1.3B in 2026Q3, while equity climbed to $1.2B, suggesting the balance sheet has grown mainly through capital raises rather than operating earnings.
The jump in assets alongside a retained deficit that widened to -$474.4M points to external funding, not internally generated value, as the driver of growth. The 2026Q1 cash peak of $627.7M followed by a drop to $55.7M by 2026Q3 implies heavy deployment into clinical operations within a few quarters. Investors should monitor whether the asset base reflects durable pipeline value or merely the cash that is being consumed.
Cash Buffer Thins Against Quarterly Burn
As reported in the balance sheet, DNTH held $55.7M in cash at 2026Q3 against a current ratio of 30.02, a liquidity profile that looks comfortable on paper but may be misleading given the scale of operating outflows.
The very high current ratio reflects a large short-term asset base relative to minimal current liabilities of roughly $34.8M total liabilities, rather than operational strength. With quarterly operating burn near $50M, cash on hand may cover only about one quarter of spending. This suggests the liquidity buffer is thin and that a near-term financing event may be required to sustain Phase 2 programs.
Minimal Debt Leaves Equity Funding Dominant
According to recent SEC filings, DNTH carried only about $1.2M of total debt at 2026Q3, with a D/E ratio near zero, indicating the company's capital structure relies almost entirely on equity rather than borrowing.
Negligible debt removes near-term refinancing risk and covenant pressure, which is a relative strength for a pre-revenue biotech. However, the absence of leverage also means the capital structure has no cushion beyond equity issuance, so dilution becomes the primary funding lever. Investors should view the low D/E as a reflection of the company's financing path rather than conservative management.
Deferred Revenue Shrinks Toward Negligible Levels
Based on reported figures, DNTH's deferred revenue fell from $7.8M in 2026Q1 to $7.0M in 2026Q3 after sitting near $740K in 2024Q3, offering little evidence of a contracted revenue backlog ahead.
The deferred revenue balance appears to be tied to legacy collaboration arrangements rather than product sales, and its recent stability does not indicate a growing forward commitment. With TTM revenue near $2.0M and declining, the forward revenue signal is weak. This suggests forward visibility depends on the pipeline reaching clinical milestones rather than on existing customer contracts.
Net Income Flattered by Non-Operating Items
As reported in the income statement, DNTH's 2025Q4 net income of $97.9M against an operating loss of -$69.5M suggests a large non-operating gain that may make the equity and retained earnings picture look better than core operations justify.
A positive net result alongside a deep operating loss implies the headline balance sheet strength may be partly driven by one-time or non-cash items rather than clinical progress. Because retained earnings still sit at -$474.4M, the accumulated deficit remains large and the underlying burn is unchanged. Investors should reconcile the equity base against the underlying operating loss before treating asset growth as evidence of durable value.